

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT EXCLUSIVE COMMERCIAL SERVICES AGREEMENT

This announcement is made on a voluntary basis by CANbridge Pharmaceuticals Inc. (北海康成製藥有限公司) (the “**Company**” and together with its subsidiaries, the “**Group**”) to provide the shareholders and potential investors of the Company with the latest information in relation to the business development of the Group.

On August 11, 2025, two subsidiaries of the Group (the “**Relevant Subsidiaries**”) has formalized a strategic relationship with a subsidiary of Qingdao Baheal Medical INC. (青島百洋醫藥股份有限公司) which is listed on the Shenzhen Stock Exchange (Stock Code: 301015) (“**Baheal Medical**” and such subsidiary being the “**Baheal Subsidiary**”). These parties have entered into a strategic collaboration and exclusive commercial services agreement (the “**Commercial Services Agreement**”) pursuant to which, the Relevant Subsidiaries have agreed to appoint the Baheal Subsidiary as the exclusive Contract Sales Organization (CSO) for the promotion of certain products of the Group in the mainland China, Hong Kong and Macau (the “**Relevant Regions**”), subject to the upstream license agreements between the relevant members of the Group and the respective licensors of these products (including the relevant licensor’s consent as applicable). It has also been agreed in the Commercial Services Agreement that the Baheal Subsidiary’s affiliates may serve as the distributor of these products in the Relevant Regions at Baheal’s option.

As the Commercial Services Agreement is of revenue nature and the entering into of such agreement is in the ordinary course of the business of the Group, the transactions contemplated under the Commercial Services Agreement do not constitute notifiable transactions of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Further, as at the date of the Commercial Services Agreement, approximately 68.40% of the shares in Baheal Medical are owned by Baheal Pharmaceutical Group Co., Ltd. (百洋醫藥集團有限公司) which is in turn ultimately controlled by Mr. Fu Gang, who is the chairman and general manager of Baheal Medical. To the best of the knowledge, information and belief of the directors of the Company, having made all reasonable enquiries, Baheal Medical and its ultimate beneficial owner are third parties independent of and not connected with the Company and its connected persons (as defined under the Listing Rules). Therefore, the transactions contemplated under the Commercial Services Agreement also do not constitute connected transactions of the Company under Chapter 14A of the Listing Rules.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, August 12, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei as non-executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.